{"id":"artesunate-vaginal-insert","safety":{"commonSideEffects":[{"rate":"10%","effect":"Nausea"},{"rate":"5%","effect":"Vomiting"},{"rate":"5%","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL361497","moleculeType":"Small molecule","molecularWeight":"384.43"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Artesunate is a potent antimalarial agent that works by inhibiting the parasite's heme detoxification system, ultimately leading to its death.","oneSentence":"Artesunate is a derivative of artemisinin that targets the heme moiety of the malaria parasite, disrupting its 80-kDa protein.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:29:24.252Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Malaria"}]},"trialDetails":[{"nctId":"NCT06519994","phase":"PHASE2","title":"Feasibility of Intravaginal Artesunate as Adjuvant HPV & Cervical Precancer Treatment in Kenya","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2025-01-22","conditions":"Human Immunodeficiency Virus, Human Papillomavirus, Cervical Precancer","enrollment":120},{"nctId":"NCT04098744","phase":"PHASE2","title":"Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3)","status":"RECRUITING","sponsor":"Frantz Viral Therapeutics, LLC","startDate":"2020-09-09","conditions":"CIN 2/3, HPV Infection, Pre-Cancerous Dysplasia","enrollment":78},{"nctId":"NCT06263582","phase":"PHASE1","title":"Pharmacokinetics of Intravaginal, Self-administered Artesunate Vaginal Pessaries Among Women in Kenya","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2024-05-29","conditions":"Cervix Cancer, Cervix Intraepithelial Neoplasia Grade 3, Cervix; Intraepithelial Neoplasia, Grade I","enrollment":12},{"nctId":"NCT06165614","phase":"PHASE1","title":"Artesunate Pessaries (Vaginal Inserts) for Cervical Precancer in Kenya","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2024-03-04","conditions":"Cervix Cancer, Cervix Neoplasm, Precancerous Conditions","enrollment":17}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Artesunic acid","DHA","artemisinin"],"phase":"phase_2","status":"active","brandName":"Artesunate vaginal insert","genericName":"Artesunate vaginal insert","companyName":"Frantz Viral Therapeutics, LLC","companyId":"frantz-viral-therapeutics-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Artesunate is a derivative of artemisinin that targets the heme moiety of the malaria parasite, disrupting its 80-kDa protein. Used for Malaria.","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}